1. Scrip

ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer

 
• By Dexter Jie Yan

In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.

ovarian cancer
Platinum-resistant ovarian cancer has a mostly poor prognosis • Source: Shutterstock

Simcere Pharmaceutical Group's novel recombinant anti-VEGF antibody suvemcitug has shown a promising overall survival trend in still immature data in platinum-resistant ovarian cancer presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, which could position it well on this benchmark against other current mainstay same-class therapies.

Key Takeaways

  • Simcere is hopeful that its anti-VEGF antibody suvemcitug in combination with chemotherapy can beat chemotherapy alone for platinum-resistant ovarian cancer.

Back in January, the Nanjing-based drug maker announced the placebo-controlled Phase III SCORES trial with suvemcitug in combination with non-platinum...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.